Globus Medical Reports First Quarter 2025 Results

Go back to Globus Medical Reports First Quarter 2025 Results

Globus Medical (GMED) PT Lowered to $78 at Oppenheimer

May 9, 2025 10:21 AM EDT

Oppenheimer analyst Steven Lichtman lowered the price target on Globus Medical (NYSE: GMED) to $78.00 (from $90.00) while maintaining a Perform rating.

The analyst commented, "Globus Medical's 1Q25 sales of $598.1 (-0.8% constant currency) missed our/Street's ~$630.1/$626M estimates. Musculoskeletal was softer on several factors including timing... More

Globus Medical (GMED) Misses Q1 EPS by 7c, Offers Guidance

May 8, 2025 4:58 PM EDT

Globus Medical (NYSE: GMED) reported Q1 EPS of $0.68, $0.07 worse than the analyst estimate of $0.75. Revenue for the quarter came in at $598.1 million versus the consensus estimate of $631.09 million.

GUIDANCE:

Globus Medical sees FY2025 EPS of $3.00-$3.30, versus the consensus of... More